Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Qihan Starts Trial of Gene-Edited iPSC-Derived NK Cell Therapy for Leukemia

publication date: Jul 20, 2023

Hangzhou Qihan Biotech has been approved to start China trials of QN-019a for CD19-positive relapsed/refractory aggressive B-cell non-Hodgkin lymphoma, the first IND approved in China for a gene-edited iPSC-derived cell therapy. Qihan uses multiplexable genome editing technology to modify human Induced Pluripotent Stem Cells (iPSCs) and differentiate them into a natural killer (NK) cell therapy product that targets CD19-positive B-cell lymphoma. Qihan uses its multiplexable genome editing technologies to create cell therapies and advance organ transplantation. Its goal is to deliver off-the-shelf cell therapies with long-term efficacy. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital